After first-line treatment and upon hematologic recovery, bone marrow aspirate and biopsy are performed to evaluate measurable residual disease (MRD) status and remission status. For patients younger than 60 years of age, post-remission therapy is also based on cytogenetics and/or molecular abnormalities.
- Timing of post-induction bone marrow assessment varies by regimen but is recommended 14-21 days* post induction, and if patient is ambiguous for hypoplasia, consider repeating after 5-7 days to determine blood count recovery and remission status before continuing treatment
Results of follow-up bone marrow aspirate, biopsy, and MRD/molecular testing guide next steps in AML treatment.
*21-28 days for patients with physiologic age <60 years after high-dose induction.